Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Botanix achieves record prescriptions for Sofdra despite temporary revenue decline

Botanix reported a record volume for Sofdra with 26,684 prescriptions delivered in the quarter and a monthly record in March, while net revenues temporarily fell from $9.1 million to $6.9 million due to the annual reset of deductibles in US health insurance plans. The GTN margin declined temporarily but is expected to normalize in the fourth quarter. The company strengthened its balance sheet with a $45 million capital raise, negotiated payment deferrals for API purchases, and signed a term-sheet agreement with Piramal that could reduce manufacturing costs by an estimated 25–40%. » Mais em de.investing.com
Botanix Pharmaceuticals achieves revenue growth and record prescription deliveries in Q3 2026

Botanix reported a gross revenue of AUD 120 million over the past 12 months and delivered 26,684 prescriptions in Q3. The gross-to-net margin improved from 16% to 19% by quarter-end, and the pro forma cash position is AUD 50.8 million. The stock fell 5% after the release. Management expects further margin improvement in Q4; projected EPS: -0.02 USD (2026) and -0.01 USD (2027), revenue forecasts: 27.71 million USD (2026) and 56.43 million USD (2027). » Mais em de.investing.com
Botanix: Sofdra revenue rises 28%, stock weighed down by higher costs

Botanix reported Q2 FY2026 net revenue of $9.1m, driven by a 24% increase in Sofdra prescriptions versus the prior quarter. The gross-to-net margin improved to 24% but remains below the 30–40% target range. Operating cash outflow rose to $17.2m after expanding the field sales force and higher operating expenses, worrying investors and sending the stock down 6%. Botanix has $31.5m in cash and $14.9m in undrawn credit lines; the challenge remains controlling costs and improving margins toward profitability. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 1996, BOTANIX PHARMACEUTICALS já distribuiu € 88,44 em dividendos. A última distribuição ocorreu em outubro de 1996.

Dados financeiros da empresa

No último trimestre, BOTANIX PHARMACEUTICALS registou receitas de € 10,91 mi e um ganho líquido de -€ 22,15 mi

(EUR)	junho de 2026	YoY
Receitas	10,91 mi	-
Ganho bruto	-18,57 mi	-
Ganho líquido	-22,15 mi	-
EBITDA	-21,62 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 23,39 mi
Número de ações	1,99 bi
Máximo/mínimo de 52 semanas	€ 0,11 - € 0,0111
Dividendos	Não
Beta	0,86
PER (PE Ratio)	-0,59
PEG (PEG Ratio)	-0,02
P/VC (PB Ratio)	0,71
P/V (PS Ratio)	1,10

Perfil da empresa

Botanix Pharmaceuticals Limited, ein pharmazeutisches Unternehmen mit synthetischen Cannabinoiden im klinischen Stadium, beschäftigt sich mit der Erforschung und Entwicklung von dermatologischen und antimikrobiellen Produkten in Australien. Zu seiner Produktpipeline gehören BTX 1503, eine transdermale Gelformulierung zur Behandlung von schwerer Akne bei Erwachsenen und Jugendlichen, die klinische Studien der Phase II abgeschlossen hat; BTX 1801, das klinische Studien der Phase IIa zur Behandlung von Staphylococcus aureus und Methicillin-resistentem Staphylococcus aureus abgeschlossen hat; BTX 1702, das sich in klinischen Studien der Phase Ib zur Behandlung von papulopustulöser Rosazea befindet; und BTX 1204A zur Behandlung von atopischer Dermatitis. Das Unternehmen wurde 1984 gegründet und hat seinen Sitz in North Perth, Australien.